Trials / Approved For Marketing

Approved For MarketingNCT04247906

Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab

Single Patient Expanded Access Treatment Plan (EAP; Also Known As A Compassionate Use Plan) To Provide Patients Access To The Investigational Product Narsoplimab

Status: Approved For Marketing
Phase: —
Study type: Expanded Access
Enrollment: —

Sponsor: Omeros Corporation · Industry
Sex: All
Age: —
Healthy volunteers: —

Summary

The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with narsoplimab based on the medical judgement of their respective physicians.

Conditions

Hematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)

Interventions

Type	Name	Description
DRUG	Narsoplimab

Timeline

First posted: 2020-01-30
Last updated: 2026-03-05

Source: ClinicalTrials.gov record NCT04247906. Inclusion in this directory is not an endorsement.